TLDR
- IBRX secures U.S. rights to Tokyo-172 BCG for high-grade bladder cancer.
- Phase III data shows Tokyo-172 BCG matches TICE BCG efficacy in trials.
- ImmunityBio plans FDA BLA submission to commercialize Tokyo-172 BCG.
- Dual partnerships ensure more reliable BCG supply for U.S. patients.
- Company advances IL-15 research and combination therapies in urology oncology.
ImmunityBio (IBRX) announced exclusive U.S. rights to develop and commercialize Tokyo-172 BCG. The agreement is with Japan BCG Laboratory (JBL), the Tokyo-based developer and manufacturer of the Tokyo strain. The Tokyo strain is investigational in the United States and not yet FDA-approved.ImmunityBio (IBRX) closed at 0.38%.
ImmunityBio, Inc., IBRX
The deal allows ImmunityBio to import, develop, and market intravesical Tokyo-172 BCG in the United States. JBL has supplied high-quality BCG products in Japan for nearly 30 years. This arrangement creates a second potential BCG source for U.S. patients beyond ImmunityBio’s existing Serum Institute partnership.
The Tokyo strain’s efficacy is supported by the February 2026 SWOG S1602 Phase III study. The study compared Tokyo-172 BCG against TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer (NMIBC). Non-inferiority was confirmed with a hazard ratio of 0.82 and a 95.8% confidence interval of 0.63–1.08.
Clinical Trial Evidence and Regulatory Path
SWOG S1602 enrolled nearly 1,000 BCG-naĂŻve NMIBC patients across three treatment arms. Tokyo-172 BCG demonstrated 64% five-year high-grade recurrence-free survival versus 58% for TICE BCG. Progression-free survival and complete response in carcinoma in situ were comparable between groups.
ImmunityBio plans to submit a Biologics License Application (BLA) to the FDA for Tokyo-172 BCG. The company will lead all clinical development, regulatory filings, and commercialization in the United States. Any FDA approval would designate ImmunityBio as the sole Marketing Authorization Holder.
The company is negotiating a Data Use Agreement with SWOG, the National Cancer Institute, and Fred Hutchinson Cancer Research Center. This agreement would allow S1602 data to be incorporated into the BLA submission. The strategy strengthens ImmunityBio’s regulatory case for expanded BCG access.
Strategic Expansion and Supply Management
ImmunityBio continues its Expanded Access Program (EAP) for recombinant BCG (rBCG) through the Serum Institute. The dual partnerships aim to address chronic BCG shortages in U.S. urology practices. Access to Tokyo-172 BCG provides an additional supply pathway while regulatory approval is pursued.
The agreement with JBL complements existing ANKTIVA approval, which treats BCG-unresponsive NMIBC in combination with BCG. ImmunityBio’s efforts focus on IL-15 research in urological oncology. This includes T cell and natural killer cell activation and emerging combination therapies.
The company’s U.S. regulatory plan is designed to ensure patients have reliable access to BCG treatments. ImmunityBio will provide updates on pre-FDA interactions and anticipated BLA submission timelines. These developments position IBRX as a central provider of innovative bladder cancer therapy in the United States.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
